Cyproterone Acetate in Advanced Ovarian Cancer
Author Information
Author(s): P. Thompson, P. Wilson, R. Osborne, M. Slevin, E. Wiltshaw, P. Blake, P. Harper, R. Coleman, C. Williams, J. Sweetenham, A. Young, R. Leonard
Primary Institution: St Bartholomew's and Homerton Hospitals, London
Hypothesis
Can cyproterone acetate provide clinical activity in patients with advanced ovarian cancer who have relapsed after platinum-based chemotherapy?
Conclusion
The study found that cyproterone acetate has some clinical activity in advanced ovarian cancer, with a low response rate but minimal toxicity.
Supporting Evidence
- Four patients experienced partial responses lasting between 2.5 and 18 months.
- Eight patients demonstrated static disease for 2 to 11 months.
- Toxicity was generally minimal, with only a few patients needing to stop treatment.
Takeaway
This study tested a medicine called cyproterone acetate to see if it helps people with a tough kind of cancer, and while it didn't help many, it was safe to use.
Methodology
Patients with advanced ovarian cancer were treated with cyproterone acetate and assessed for response and toxicity using standard criteria.
Limitations
The response rate was low, and many patients had been extensively pretreated, which may affect the generalizability of the results.
Participant Demographics
Patients were primarily women with advanced ovarian cancer, some of whom were too frail for platinum-based chemotherapy.
Want to read the original?
Access the complete publication on the publisher's website